Pfizer Inc.✓

See how Pfizer is using AI to help support precise and efficient manufacturing through our #GoldenBatch platform by turning complex production data into actionable insights. #ArtificialIntelligence #Manufacturing

Obesity isn’t simply about weight. It’s linked to inflammation, insulin resistance, and 200+ other conditions. Pfizer’s Lisa Tarasenko explains why treating obesity as a chronic disease, not a personal failing, is reshaping care. #ObesityCare #ChronicDisease

Obesity isn’t a failure of willpower—it’s a chronic, multifactorial disease. Once weight is gained, the body works hard to keep it. Pfizer’s Dr. Manige Konig on what the science now tells us: #Obesity #WeightStigma

When Josh Raub was diagnosed with Hodgkin lymphoma at age 29, he wondered if he would ever have a family. Today, the father of two has been in complete remission for 12 years. He reflects on what matters most:

Finding participants is one of the biggest challenges in clinical research. #AI has the potential to help researchers identify potentially eligible volunteers faster, improve trial planning, and reduce administrative burden while keeping researchers and patients at the center of every decision. Learn more:

💊 Most people never question whether the medicine in their cabinet is real, but the illicit worldwide counterfeit drugs network is vast, adaptive, and relentless. Here's how we’re helping combat counterfeits, disrupt criminal networks, and protect patients:

250 years of American innovation have shown what’s possible when different minds and ideas come together. As we look to what’s next, Pfizer is proud to build on that spirit of innovation, continuing to advance science and explore what’s possible for the future of medicine. #America250

Every dose of medicine you take is the final step in a long journey—one that runs through qualified suppliers, rigorous testing, and continuous monitoring. Pfizer's Bina Nair and Kenya Edmondson walk through what it takes to make sure every dose performs the same way, everywhere: #PharmaManufacturing #QualityAssurance

For more than a century, scientists studied cancer as a caricature of healthy tissue. Spatial transcriptomics is changing that. Now, with the ability to map tumors cell by cell, researchers are rethinking what’s possible in cancer treatment. Read more: #Oncology #CancerResearch #PrecisionMedicine

Most scientific discoveries begin in a lab. Reaching patients requires something else entirely: a global system built to produce medicines consistently, at scale, without ever compromising on quality. Read more: #GlobalHealth #PatientAccess

Pfizer Chief Oncology Officer Jeff Legos joined @TIME CEO Jessica Sibley ahead of #ESMO26 to discuss the future of cancer care and the urgency behind oncology innovation. Watch the conversation:

Why do we weigh what we weigh? ⚖️ Season 7 of #ScienceWillWin explores the science behind #obesity—from hunger and hormones to genetics and real patient stories. Hosted by @DrJoeHanson of PBS's Be Smart. Coming soon. 🎧 Listen to the trailer today:

This #BreastCancerAwarenessMonth, explore Moments Beyond Cancer — a new initiative highlighting small, everyday actions to help people with #MetastaticBreastCancer maintain a sense of self beyond their diagnosis:

Meet the people behind the science. This #WorldCancerResearchDay, our colleagues share what inspires them to advance cancer research and pursue breakthroughs that change patients’ lives.

Empowerment starts with education. From understanding routine #ProstateCancer screenings to next steps after a diagnosis, knowledge can help clarify the path ahead. This #ProstateCancerAwarenessMonth, learn how to take an active role in care at

When prostate cancer becomes resistant to traditional hormone therapies, new treatment approaches are needed. Pfizer researchers are studying EZH2 and exploring ways to potentially reprogram treatment resistance in metastatic prostate cancer. Learn more:

What is one challenge in ATTR-CM you would like to highlight? At #ESCCongress in Munich, leading clinicians in the field told us what they thought. At Pfizer, we are committed to advancing understanding and awareness of ATTR-CM to improve outcomes for patients.

As #ESCCongress 2026 returns to Munich, early diagnosis and treatment initiation remain the biggest opportunity to improve outcomes in ATTR-CM, an underdiagnosed cause of heart failure. Explore how the landscape has evolved and what needs to happen next:

Our global survey found unspoken compromises may persist in hemophilia care, pointing to a need for more open conversations. With 6 in 10 patients saying HCPs are their primary source of information on newer treatments, shared-decision making can help evolve care. See more:

RT @AlbertBourla: Our second quarter results are out today, and I am proud to report another strong quarter of execution. Thank you to my @pfizer colleagues, all of you, for everything behind these results and for your commitment to our purpose: breakthroughs that change patients’ lives.